AU2012225277A1 - Protein nanoparticle dispersions - Google Patents

Protein nanoparticle dispersions Download PDF

Info

Publication number
AU2012225277A1
AU2012225277A1 AU2012225277A AU2012225277A AU2012225277A1 AU 2012225277 A1 AU2012225277 A1 AU 2012225277A1 AU 2012225277 A AU2012225277 A AU 2012225277A AU 2012225277 A AU2012225277 A AU 2012225277A AU 2012225277 A1 AU2012225277 A1 AU 2012225277A1
Authority
AU
Australia
Prior art keywords
dispersion
protein
nanoclusters
crowder
viscosity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012225277A
Other languages
English (en)
Inventor
Ameya BORWANKAR
Aileen DININ
Keith P. Johnston
Jennifer A. Maynard
Andrea Miller
Thomas M. Truskett
Brian Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2012225277A1 publication Critical patent/AU2012225277A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2012225277A 2011-03-10 2012-03-09 Protein nanoparticle dispersions Abandoned AU2012225277A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161451571P 2011-03-10 2011-03-10
US61/451,571 2011-03-10
US201261587648P 2012-01-17 2012-01-17
US61/587,648 2012-01-17
PCT/US2012/028640 WO2012122544A2 (en) 2011-03-10 2012-03-09 Protein nanoparticle dispersions

Publications (1)

Publication Number Publication Date
AU2012225277A1 true AU2012225277A1 (en) 2013-09-26

Family

ID=46795761

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012225277A Abandoned AU2012225277A1 (en) 2011-03-10 2012-03-09 Protein nanoparticle dispersions

Country Status (6)

Country Link
US (1) US20120230913A1 (enExample)
EP (1) EP2683362A4 (enExample)
JP (1) JP2014514275A (enExample)
AU (1) AU2012225277A1 (enExample)
CA (1) CA2829629A1 (enExample)
WO (1) WO2012122544A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
US20110229957A1 (en) * 2010-03-17 2011-09-22 Lehigh University Polymer-mediated electromagnetic field-based particle concentrator
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP3613413A1 (en) 2011-12-05 2020-02-26 Incept, LLC Medical organogel processes and compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US20130336957A1 (en) * 2012-05-21 2013-12-19 Abbvie, Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9677869B2 (en) 2012-12-05 2017-06-13 Perimeter Medical Imaging, Inc. System and method for generating a wide-field OCT image of a portion of a sample
CN103886226A (zh) * 2012-12-21 2014-06-25 中国科学院大连化学物理研究所 基于三维空间静电势重构的新型蛋白质粗粒化计算方法
CN103083659B (zh) * 2013-01-18 2015-05-13 北京华夏兴洋生物科技有限公司 新型无油佐剂制备方法及用途
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2796144A1 (en) 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
JP6213113B2 (ja) * 2013-09-30 2017-10-18 ブラザー工業株式会社 液体吐出記録装置及び液体回収方法
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP6338869B2 (ja) * 2014-01-28 2018-06-06 国立研究開発法人産業技術総合研究所 粒径分布計測方法
JP6554493B2 (ja) 2014-06-24 2019-07-31 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス
US20160058863A1 (en) * 2014-09-03 2016-03-03 Board Of Regents, The University Of Texas System Low viscosity concentrated protein dispersions
CN105031645B (zh) * 2015-07-09 2018-08-17 宁波荣安生物药业有限公司 一种人用狂犬病疫苗及其制备方法
JP6910029B2 (ja) * 2015-08-17 2021-07-28 国立研究開発法人科学技術振興機構 ナノクラスター分散液、ナノクラスター膜、ナノクラスター分散体、ナノクラスター分散液の製造方法およびナノクラスター分散液の製造装置
JP2017110001A (ja) * 2015-12-16 2017-06-22 株式会社 資生堂 タブレット型凍結乾燥化粧料
US11103461B2 (en) 2015-12-22 2021-08-31 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
MA46466A (fr) * 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
CN106492715B (zh) * 2016-12-19 2023-02-10 广东工业大学 一种制备微粒的方法及装置
WO2019018446A1 (en) 2017-07-17 2019-01-24 Fractal Heatsink Technologies, LLC SYSTEM AND METHOD FOR MULTI-FRACTAL THERMAL DISSIPATOR
EP3655748B1 (en) 2017-07-18 2023-08-09 Perimeter Medical Imaging, Inc. Sample container for stabilizing and aligning excised biological tissue samples for ex vivo analysis
KR101959812B1 (ko) * 2017-09-01 2019-03-19 성균관대학교 산학협력단 유기 발광 소자
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
JP2021501753A (ja) 2017-11-03 2021-01-21 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿
WO2019191531A1 (en) 2018-03-30 2019-10-03 Idexx Laboratories, Inc. Quality control for point-of-care diagnostic systems
US12186436B2 (en) 2018-07-19 2025-01-07 The Trustees Of Princeton University Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US12036280B2 (en) * 2018-11-21 2024-07-16 Regeneron Pharmaceuticals, Inc. High concentration protein formulation
US20210386680A1 (en) * 2018-12-06 2021-12-16 Board Of Regents, The University Of Texas System Selectively cleavable therapeutic nanoparticles
CN110823820A (zh) * 2019-10-17 2020-02-21 浙江工业大学 用于cod测量中的浊度干扰消除方法
CN111665217A (zh) * 2020-06-09 2020-09-15 吉林省农业科学院 一种大豆种子蔗糖含量的近红外光谱检测方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0899897A (ja) * 1994-08-05 1996-04-16 Shionogi & Co Ltd インターロイキン−２吸着型脂質小球体
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
AU2003291527A1 (en) * 2002-12-31 2004-07-29 Nektar Therapeutics Antibody-containing particles and compositions
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
EP1968550A2 (en) * 2005-12-16 2008-09-17 University Of Kansas Nanoclusters for delivery of therapeutics
WO2010009146A1 (en) * 2008-07-15 2010-01-21 University Of Kansas Nanoclusters for delivery of poorly water soluble drug nanoparticles
WO2007072982A1 (en) * 2005-12-20 2007-06-28 Fujifilm Corporation Protein nanoparticles and the use of the same
JP2009173610A (ja) * 2008-01-28 2009-08-06 Fujifilm Corp タンパク質ナノ粒子
AU2009244742B2 (en) * 2008-05-09 2014-11-06 South Dakota State University Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor
JP5711138B2 (ja) * 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
US8399406B2 (en) * 2009-06-05 2013-03-19 Chiesi Farmaceutici S.P.A. Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C)

Also Published As

Publication number Publication date
WO2012122544A2 (en) 2012-09-13
CA2829629A1 (en) 2012-09-13
EP2683362A2 (en) 2014-01-15
US20120230913A1 (en) 2012-09-13
JP2014514275A (ja) 2014-06-19
EP2683362A4 (en) 2014-09-17
WO2012122544A3 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
US20120230913A1 (en) Protein nanoparticle dispersions
Ma et al. Overcoming multidrug resistance through the GLUT1-mediated and enzyme-triggered mitochondrial targeting conjugate with redox-sensitive paclitaxel release
CN105611938B (zh) 稳定的水性抗体配制品
CN114514035A (zh) 递送用于治疗疾病的治疗性生物制剂的组合物和方法
Schmitt et al. Finding the needle in the haystack: characterization of trace crystallinity in a commercial formulation of paclitaxel protein-bound particles by Raman spectroscopy enabled by second harmonic generation microscopy
Moreno et al. Study of stability and biophysical characterization of ranibizumab and aflibercept
TWI764097B (zh) 包含抗ｃｄ４７抗體的製劑及其製備方法和用途
RS56362B1 (sr) Terapeutske polimerne nanočestice i postupci njihove pripreme i primene
Taka et al. Ocular co-delivery of timolol and brimonidine from a self-assembling peptide hydrogel for the treatment of glaucoma: in vitro and ex vivo evaluation
Hu et al. Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury
US10500226B2 (en) Alginate compositions and uses thereof
Wei et al. Developing biologics tablets: the effects of compression on the structure and stability of bovine serum albumin and lysozyme
EP4070817A1 (en) Liquid preparation containing anti-il-17 antibody
TWI802942B (zh) Pd-l1/lag-3雙特異性抗體製劑及其製備方法和用途
WO2022254209A1 (en) Stable composition
Yadav et al. Development and approval of novel injectables: enhancing therapeutic innovations
EP3060256B1 (en) A novel stable formulation
Wang et al. Efficiency encapsulation of FK506 with new dual self‐assembly multi‐hydrophobic‐core nanoparticles for preventing keratoplasty rejection
Miller et al. Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and in vivo bioavailability
Ji et al. Engineering telodendrimer nanocarriers for monomeric amphotericin B delivery
US20240252596A1 (en) Injectable Polymeric Biopharmaceutical Formulations
Lu et al. Mechanistic investigation of drug supersaturation in the presence of polysorbates as solubilizing additives by solution nuclear magnetic resonance spectroscopy
CN103536898A (zh) 胸腺五肽药物组合物
Gao et al. Effect of annealing on visible-bubble formation and stability profiles of freeze-dried high concentration omalizumab formulations
Xu et al. Stability of intravenous antibody dilutions in clinical use: Differences across patient populations with varying body weights

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period